 |
|
|
|
Clinical Trials For NPI-2358 (VDA)
Nereus Pharmaceuticals is currently enrolling patients in a Phase I clinical
trial of NPI-2358. This trial is a dose-escalation study in patients with
advanced solid tumors or lymphoma. This clinical study will assess the
pharmacokinetics, pharmacodynamics, safety, toxicity, and maximum tolerated dose
of NPI-0052 when administered intravenously. Subsequent to determining the
maximum tolerated dose, 12 additional patients will be entered to gain
preliminary data on efficacy. DCE-MRI scans are also performed during the trial
to assess the effect of NPI-2358 on blood flow in tumors.
To learn more about these clinical trials please visit
www.clinicaltrials.gov .
- Nereus Pharmaceutical drugs are in preclinical or clinical trail
testing, and are not available by prescription from doctors. Patients can
only receive these drugs if they are participating in a sponsored clinical
trial.
- If you are a patient and interested in entering a clinical trial,
it is best that you consult your doctor regarding appropriate and available
treatments for your condition, and whether or not you should enter a
clinical trial. Your physician can find a description and list of
participating centers for clinical trials sponsored by Nereus
Pharmaceuticals, as well as other clinical trials for patients with cancer,
at www.clinicaltrials.gov.
- Nereus pharmaceuticals cannot respond to patient inquiries on
medical matters.
- Clinical trials can only be entered by contacting participating
physicians and centers. Patients cannot enter clinical trials by contacting
Nereus Pharmaceuticals.
|
|
|
